Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Nedosiran (RIVFLOZA™), a once-monthly subcutaneous small interfering RNA (siRNA) therapy, is being developed by Dicerna Pharmaceuticals, a Novo Nordisk company, for the treatment of primary hyperoxaluria (PH). It reduces oxalate overproduction by inhibiting the expression of the hepatic lactate dehydrogenase (LDH) enzyme. Nedosiran received its first approval on 29 September 2023 in the USA to lower urinary oxalate levels in children aged ≥ 9 years and adults with PH type 1 (PH1) and relatively preserved kidney function [e.g. estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m]. This article summarizes the milestones in the development of nedosiran leading to this first approval for PH1.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10803381 | PMC |
| http://dx.doi.org/10.1007/s40265-023-01976-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1.
Kidney Int Rep
June 2025
German Hyperoxaluria Center, Bonn, Germany.
Introduction: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease characterized by oxalate overproduction in the liver, leading to hyperoxaluria, calcium oxalate stones, nephrocalcinosis, progressive chronic kidney damage, kidney failure, and systemic oxalate deposition. Nedosiran, an RNA interference therapy against lactate dehydrogenase subunit A mRNA, has been approved in the USA for treating patients with PH1 who are aged ≥ 9 years and have an estimated glomerular filtration rate (eGFR) ≥ 30 ml/min per 1.73 m.
View Article and Find Full Text PDFPopulation Pharmacokinetic and Pharmacodynamic Modelling and Simulation for Nedosiran Clinical Development and Dose Guidance in Pediatric Patients with Primary Hyperoxaluria Type 1.
Clin Pharmacokinet
September 2025
Novo Nordisk Inc., 75 Hayden Avenue, Lexington, MA, 02421, USA.
Background And Objectives: Nedosiran (Rivfloza) is an RNA interference (RNAi) therapy approved for individuals aged ≥ 2 years with primary hyperoxaluria type 1 (PH1), a rare autosomal-recessive disorder causing renal failure and systemic oxalosis. Nedosiran silences lactate dehydrogenase (LDH) mRNA in hepatocytes, reducing oxalate levels. This study evaluated the model-informed clinical development of nedosiran to support proposed doses in children aged 2 to < 12 years with PH1.
View Article and Find Full Text PDFTreatment preferences among individuals with primary hyperoxaluria type 1 (PH1): a real-world study.
Orphanet J Rare Dis
May 2025
Division of Nephrology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, USA.
Background: Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder causing excessive oxalate production, damaging kidneys and other organs. Nedosiran, launched in the U.S.
View Article and Find Full Text PDFThe efficacy and safety of RNA interference for the treatment of primary hyperoxaluria: a systematic review and meta-analysis.
Clin Kidney J
April 2025
Department of Nephrology, Yunfu People's Hospital, Yunfu, Guangdong, People's Republic of China.
Primary hyperoxaluria (PH) are rare inherited disorders of liver glyoxylate metabolism. The main symptoms are related to the precipitation of calcium oxalate crystals in the urinary tract with progressive renal damage. The severity of disease can result in kidney failure and systemic oxalosis.
View Article and Find Full Text PDF